CA3151637A1 - Methods of treating vascular diseases - Google Patents

Methods of treating vascular diseases Download PDF

Info

Publication number
CA3151637A1
CA3151637A1 CA3151637A CA3151637A CA3151637A1 CA 3151637 A1 CA3151637 A1 CA 3151637A1 CA 3151637 A CA3151637 A CA 3151637A CA 3151637 A CA3151637 A CA 3151637A CA 3151637 A1 CA3151637 A1 CA 3151637A1
Authority
CA
Canada
Prior art keywords
mirna
res
cells
hsa
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3151637A
Other languages
English (en)
French (fr)
Inventor
Nagisa SAKURAI
Maria Mirotsou
Nutan PRASAIN
Amrita Singh
Robert Lanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Publication of CA3151637A1 publication Critical patent/CA3151637A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Reproductive Health (AREA)
  • Materials For Medical Uses (AREA)
  • Gynecology & Obstetrics (AREA)
CA3151637A 2019-08-28 2020-08-27 Methods of treating vascular diseases Pending CA3151637A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892712P 2019-08-28 2019-08-28
US62/892,712 2019-08-28
PCT/US2020/048080 WO2021041592A1 (en) 2019-08-28 2020-08-27 Methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
CA3151637A1 true CA3151637A1 (en) 2021-03-04

Family

ID=72422305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3151637A Pending CA3151637A1 (en) 2019-08-28 2020-08-27 Methods of treating vascular diseases

Country Status (10)

Country Link
US (1) US20220280572A1 (cg-RX-API-DMAC7.html)
EP (1) EP4022042A1 (cg-RX-API-DMAC7.html)
JP (1) JP7876440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054359A (cg-RX-API-DMAC7.html)
CN (1) CN115003800A (cg-RX-API-DMAC7.html)
AU (1) AU2020337929B2 (cg-RX-API-DMAC7.html)
CA (1) CA3151637A1 (cg-RX-API-DMAC7.html)
IL (1) IL290892A (cg-RX-API-DMAC7.html)
TW (1) TW202122577A (cg-RX-API-DMAC7.html)
WO (1) WO2021041592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
US20230027007A1 (en) * 2021-07-02 2023-01-26 Regeneron Pharmaceuticals, Inc. Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
CN116832051B (zh) * 2023-07-08 2024-02-09 首都医科大学 抗氧化抗炎和促脂质代谢协同纳米给药系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070083A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Endothelial precursor cells for enhancing and restoring vascular function
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
CN101534747A (zh) * 2006-07-10 2009-09-16 哥伦比亚大学 从组织祖细胞和血管祖细胞从头形成和再生血管化组织
BRPI0912201A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc células formadoras de colônias de hemangios e células de hemangio não enxertantes
KR101920891B1 (ko) * 2010-08-27 2018-11-21 조슈아 엠 헤어 심장 치료를 위한 골수 유래 ｃｄ271 전구 세포
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US9428732B2 (en) * 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
JP6746313B2 (ja) * 2012-08-01 2020-08-26 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
CA2896053A1 (en) * 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2970912B1 (en) * 2013-03-13 2019-03-06 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
CA2930304A1 (en) * 2013-11-13 2015-05-21 Cornell University Post-natal hematopoeitic endothelial cells and their isolation and use
US10626372B1 (en) * 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP3383182B1 (en) * 2015-12-03 2023-06-07 The Brigham and Women's Hospital, Inc. Methods for generating functional hematopoietic stem cells
US11345895B2 (en) * 2016-11-18 2022-05-31 Wisconsin Alumni Research Foundation Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways

Also Published As

Publication number Publication date
TW202122577A (zh) 2021-06-16
WO2021041592A9 (en) 2021-06-24
AU2020337929B2 (en) 2026-07-16
US20220280572A1 (en) 2022-09-08
JP2022547832A (ja) 2022-11-16
WO2021041592A1 (en) 2021-03-04
AU2020337929A1 (en) 2022-03-24
JP7876440B2 (ja) 2026-06-19
KR20220054359A (ko) 2022-05-02
EP4022042A1 (en) 2022-07-06
CN115003800A (zh) 2022-09-02
WO2021041592A8 (en) 2021-04-01
IL290892A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CA2701435C (en) Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
JP6647863B2 (ja) 肺疾患及び肺障害の炎症促進性メディエータのｈＵＴＣ調節
Murry et al. Regeneration gaps: observations on stem cells and cardiac repair
JP4948165B2 (ja) 心臓及び循環器系疾患の治療において使用するための分娩後由来細胞
US10787641B2 (en) Therapeutic use of CD31 expressing cells
JP6571537B2 (ja) 療法および予防のための細胞を単離する方法
Avolio et al. Stem cell therapy and tissue engineering for correction of congenital heart disease
Bollini et al. In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells
US20220280572A1 (en) Methods of treating vascular diseases
HK1216235A1 (zh) 使用产後衍生细胞治疗外周血管疾病
KR20140054206A (ko) 제대 조직―유래 세포를 사용한 말초 혈관 질환의 치료
CN115003794A (zh) 治疗血管疾病的组合物和方法
JP2012532609A (ja) 心臓組織由来細胞
US10011820B2 (en) Adipose stromal vascular fraction cell constructs
US9901639B2 (en) Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
RU2843942C2 (ru) Композиции и способы лечения сосудистых заболеваний
Hong et al. Enhanced intramyocardial vascular cell delivery promotes post-myocardial infarction healing by polarizing pro-regenerative neutrophils
Garcia Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
Rao Epicardial cell engraftment and signaling promote cardiac repair after myocardial infarction
Singh et al. New directions in cardiac stem cell therapy: An update for clinicians
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kit
Poole Cardiovascular therapeutics derived from the paracrine biology of adult human progenitor cells
Gambini Isolation, characterization and ex vivo amplification of heart-derived c-kit progenitor cells for cellular therapy
Ostojic Use of a collagen I matrix to enhance the potential of circulating angiogenic cells (CACs) for therapy
Zhang et al. A novel population of human bone marrow multipotent mesenchymal stem cells regenerates infarcted myocardium in rats

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240823

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250523

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260602